Byetta
A model of exentide-4 (Byetta) based upon the NMR structure of a related peptide GLP-1. Byetta was developed by Amylin Pharmaceuticals as a drug for use in the treatment of Type II diabetes. The sculpture represents 6 of the 36 structures that were consistent with the NMR derived distance constraints.